Campos de Carvalho Antonio Carlos, Kasai-Brunswick Tais H, Bastos Carvalho Adriana
Laboratory of Cellular and Molecular Cardiology, Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
National Center of Structural Biology and Bioimaging (CENABIO), Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Front Pharmacol. 2021 Apr 12;12:641116. doi: 10.3389/fphar.2021.641116. eCollection 2021.
Heart failure has reached epidemic proportions with the advances in cardiovascular therapies for ischemic heart diseases and the progressive aging of the world population. Efficient pharmacological therapies are available for treating heart failure, but unfortunately, even with optimized therapy, prognosis is often poor. Their last therapeutic option is, therefore, a heart transplantation with limited organ supply and complications related to immunosuppression. In this setting, cell therapies have emerged as an alternative. Many clinical trials have now been performed using different cell types and injection routes. In this perspective, we will analyze the results of such trials and discuss future perspectives for cell therapies as an efficacious treatment of heart failure.
随着缺血性心脏病心血管治疗方法的进步以及世界人口的不断老龄化，心力衰竭已达到流行程度。目前有有效的药物疗法可用于治疗心力衰竭，但不幸的是，即使采用优化治疗，预后往往也很差。因此，他们最后的治疗选择是心脏移植，而心脏移植存在器官供应有限以及与免疫抑制相关的并发症等问题。在这种情况下，细胞疗法应运而生。现在已经使用不同的细胞类型和注射途径进行了许多临床试验。从这个角度出发，我们将分析这些试验的结果，并讨论细胞疗法作为心力衰竭有效治疗方法的未来前景。
